Changes in heart transplant waitlist and posttransplant outcomes in patients with restrictive and hypertrophic cardiomyopathy with the new heart transplant allocation system.

clinical research/practice heart transplantation hypertrophic cardiomyopathy organ allocation restrictive cardiomyopathy waitlist management

Journal

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
ISSN: 1600-6143
Titre abrégé: Am J Transplant
Pays: United States
ID NLM: 100968638

Informations de publication

Date de publication:
03 2021
Historique:
received: 13 07 2020
revised: 24 08 2020
accepted: 14 09 2020
pubmed: 27 9 2020
medline: 22 6 2021
entrez: 26 9 2020
Statut: ppublish

Résumé

Historically, patients with restrictive (RCM) and hypertrophic cardiomyopathy (HCM) experienced longer wait-times for heart transplant (HT) and increased waitlist mortality. Recently, a new HT allocation system was implemented in the United States. We sought to determine the impact of the new HT system on RCM/HCM patients. Adult patients with RCM/HCM listed for HT between November 2015 and September 2019 were identified from the UNOS database. Patients were stratified into two groups: old system and new system. We identified 872 patients who met inclusion criteria. Of these, 608 and 264 were classified in the old and new system groups, respectively. The time in the waitlist was shorter (25 vs. 54 days, P < .001), with an increased frequency of HT in the new system (74% vs. 68%, P = .024). Patients who were transplanted in the new system had a longer ischemic time, increased use of temporary mechanical circulatory support and mechanical ventilation. There was no difference in posttransplant survival at 9 months (91.1% vs. 88.9%) (p = .4). We conclude that patients with RCM/HCM have benefited from the new HT allocation system, with increased access to HT without affecting short-term posttransplant survival.

Identifiants

pubmed: 32978873
doi: 10.1111/ajt.16325
pii: S1600-6135(22)08459-3
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1255-1262

Informations de copyright

© 2020 The American Society of Transplantation and the American Society of Transplant Surgeons.

Références

Sridharan L, Wayda B, Truby LK, et al. Mechanical circulatory support device utilization and heart transplant waitlist outcomes in patients with restrictive and hypertrophic cardiomyopathy. Circ Heart Fail. 2018;11(3):e004665.
Hsich EM, Rogers JG, McNamara DM, et al. Does survival on the heart transplant waiting list depend on the underlying heart disease? JACC Heart Fail. 2016;4(9):689-697.
Panhwar MS, Al-Kindi SG, Tofovic D, Oliveira GH, Ginwalla M. Waitlist mortality of patients with amyloid cardiomyopathy who are listed for heart transplantation and implications for organ allocation. J Cardiac Fail. 2019;25(9):767-771.
Zuniga Cisneros J, Stehlik J, Selzman CH, Drakos SG, McKellar SH, Wever-Pinzon O. Outcomes in patients with hypertrophic cardiomyopathy awaiting heart transplantation. Circ Heart Fail. 2018;11(3):e004378.
Grupper A, Park SJ, Pereira NL, et al. Role of ventricular assist therapy for patients with heart failure and restrictive physiology: improving outcomes for a lethal disease. J Heart Lung Transplant. 2015;34(8):1042-1049.
Teuteberg JJ, Cleveland JC Jr, Cowger J, et al. The Society of Thoracic surgeons intermacs 2019 annual report: the changing landscape of devices and indications. Ann Thorac Surg. 2020;109(3):649-660.
Loyaga-Rendon RY, Boeve T, Tallaj J, et al. ,Response by Loyaga-Rendon et al. to Letter Regarding Article, "Extracorporeal Membrane Oxygenation as a Bridge to Durable Mechanical Circulatory Support: An Analysis of the STS INTERMACS Database". Circ Heart Fail. 2020;13(7):e007194.
Givertz MM. Heart allocation in the United States: intended and unintended consequences. Circ Heart Fail. 2012;5(2):140-143.
Meyer DM, Rogers JG, Edwards LB, et al. The future direction of the adult heart allocation system in the United States. Am J Transplant. 2015;15(1):44-54.
Stevenson LW, Kormos RL, Young JB, Kirklin JK, Hunt SA. Major advantages and critical challenge for the proposed United States heart allocation system. J Heart Lung Transplant. 2016;35(5):547-549.
Pasqualucci D, Fornaro A, Castelli G, et al. Clinical spectrum, therapeutic options, and outcome of advanced heart failure in hypertrophic cardiomyopathy. Circ Heart Fail. 2015;8(6):1014-1021.
Topilsky Y, Pereira NL, Shah DK, et al. Left ventricular assist device therapy in patients with restrictive and hypertrophic cardiomyopathy. Circ Heart Fail. 2011;4(3):266-275.
Patel SR, Saeed O, Naftel D, et al. Outcomes of restrictive and hypertrophic cardiomyopathies after LVAD: an INTERMACS analysis. J Cardiac Fail. 2017;23(12):859-867.
Mehra MR, Canter CE, Hannan MM, et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update. J Heart Lung Transplant. 2016;35(1):1-23.
Arabia FA, Cantor RS, Koehl DA, et al. Interagency registry for mechanically assisted circulatory support report on the total artificial heart. J Heart Lung Transplant. 2018;37(11):1304-1312.
Ong KC, Geske JB, Hebl VB, et al. Pulmonary hypertension is associated with worse survival in hypertrophic cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2016;17(6):604-610.
Varshney AS, Berg DD, Katz JN, et al. Use of temporary mechanical circulatory support for management of cardiogenic shock before and after the United Network for Organ Sharing Donor Heart Allocation system changes. JAMA Cardiol. 2020;5(6):703-708.
Yin MY, Wever-Pinzon O, Mehra MR, et al. Post-transplant outcome in patients bridged to transplant with temporary mechanical circulatory support devices. J Heart Lung Transplant. 2019;38(8):858-869.
Cogswell R, John R, Estep JD, et al. An early investigation of outcomes with the new 2018 donor heart allocation system in the United States. J Heart Lung Transplant. 2020;39(1):1-4.
Hanff TC, Harhay MO, Kimmel SE, Birati EY, Acker MA. Update to an early investigation of outcomes with the new 2018 donor heart allocation system in the United States. J Heart Lung Transplant. 2020.39(7):725-726.
Parker WF, Churpek MM, Anderson AS. Is it too early to investigate survival outcomes of the new US heart allocation system? J Heart Lung Transplant. 2020.39(7):726

Auteurs

Renzo Y Loyaga-Rendon (RY)

Advanced Heart Failure Section, Spectrum Health, Michigan State University, Grand Rapids, Michigan.

David Fermin (D)

Advanced Heart Failure Section, Spectrum Health, Michigan State University, Grand Rapids, Michigan.

Milena Jani (M)

Advanced Heart Failure Section, Spectrum Health, Michigan State University, Grand Rapids, Michigan.

Matthew Gonzalez (M)

Advanced Heart Failure Section, Spectrum Health, Michigan State University, Grand Rapids, Michigan.

Ryan Grayburn (R)

Advanced Heart Failure Section, Spectrum Health, Michigan State University, Grand Rapids, Michigan.

Sangjin Lee (S)

Advanced Heart Failure Section, Spectrum Health, Michigan State University, Grand Rapids, Michigan.

Michael G Dickinson (MG)

Advanced Heart Failure Section, Spectrum Health, Michigan State University, Grand Rapids, Michigan.

Nabin K Manandhar-Shrestha (NK)

Department of Cardiovascular Research, Spectrum Health, Grand Rapids, Michigan.

Theodore Boeve (T)

Division of Cardio Thoracic Surgery, Spectrum Health, Grand Rapids, Michigan.

Stefan Jovinge (S)

Frederik Meijer Heart and Vascular Institute, Spectrum Health, Grand Rapids, Michigan.
DeVos Cardiovascular Research Program, Van Andel Institute/Spectrum Health, Grand Rapids, Michigan.
Cardiovascular Institute, Stanford University, Palo Alto, California.

Marzia Leacche (M)

Division of Cardio Thoracic Surgery, Spectrum Health, Grand Rapids, Michigan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH